Full-Time

Associate Director

Learning & Development, Marketing Excellence, Global Capability Op Model & Data

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$156k - $234k/yr

+ Discretionary Annual Cash Bonus + Discretionary Equity Grants

Pennsylvania, USA

Remote

US-based, home-based in Pennsylvania; travel up to 50-60% locally/visits as needed.

Bachelor's, MBA

Category
Business & Strategy (1)
Required Skills
Branding/Brand Strategy
Data Governance
Data Analysis

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Requirements
  • Bachelor's degree in business, healthcare, technology, or related field
  • 10 years of industry experience in marketing, preferably in specialty pharmaceuticals/biotech, data and/or IT related roles
  • 2+ years of experience in training, with a proven track record of developing and delivering engaging training solutions using adult learning principles and distance learning methodologies
Responsibilities
  • Own and execute the enterprise learning and adoption strategy for Marketing Excellence capabilities, establishing global curricula, capability development pathways, and role-based learning experiences that progress from foundational to advanced levels and align with commercial priorities, capability roadmaps, and transformation initiatives.
  • Serve as the strategic advisor to Commercial Leadership, Global Capability leaders, and franchise leadership on marketing capability development priorities and organizational readiness.
  • Design and scale role-based onboarding and capability development programs that strengthen core marketing excellence skills—including brand strategy, insight-driven planning, executional excellence, analytics, and decision-making—by translating frameworks, playbooks, and best practices into practical learning experiences.
  • Lead enterprise adoption of Marketing Excellence standards, new ways of working, and customer engagement models through integrated learning, performance consulting, change management, and capability-building interventions that drive sustained behavior change, operational excellence, and business readiness.
  • Partner with Global Capability, Commercial, Analytics, Brand, and Data & Enablement leaders to develop learning solutions that build understanding and adoption of the Global Capability Operating Model, including roles, responsibilities, decision rights, and enterprise ways of working.
  • Develop and oversee learning programs that enable marketers to understand, access, interpret, and appropriately apply commercial data assets, including data governance principles, ownership models, access requirements, limitations, and intended business use.
  • Present capability insights, adoption metrics, risks, recommendations, and organizational readiness assessments to executive leadership teams.
  • Facilitate leadership alignment around capability evolution, organizational readiness, and performance improvement opportunities.
  • Establish measurement frameworks to assess learning effectiveness, capability adoption, behavior change, and organizational impact; leverage stakeholder feedback, performance metrics, and emerging industry trends to continuously evolve learning priorities and programs.
  • Build organizational capability within the Learning & Development function through mentoring, knowledge sharing, and best-practice development.
  • Collaborate cross‑functionally with Franchises, Customer Insights & Analytics, Legal, and Compliance to ensure marketing excellence content is accurate, practical, and compliant
  • Collaborate cross‑functionally with Global Capability Teams, DEC, and Compliance partners to ensure accuracy, alignment, and appropriate use guidance.
  • Collaborate with adjacent L&D team members to ensure alignment across curricula.
  • Engage regional stakeholders to drive consistent adoption while accounting for local needs.
  • Share insights, risks, and lessons learned with CX peers and team leadership to support alignment and continuous improvement
Desired Qualifications
  • Advanced degree (MBA or relevant graduate degree) preferred.
  • Leadership experience in marketing preferred, including strategy development and cross-functional collaboration to drive marketing effectiveness and capability building.
  • Experience working in a product operating model.
  • Experience in healthcare, pharmaceutical, or other highly regulated industries preferred.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue hit $1.21 billion, and guidance rose to $4.75 billion.
  • Zepzelca grew 60% in Q1 2026 on first-line maintenance adoption.
  • Zanidatamab gained FDA Priority Review, positioning Jazz for a near-term oncology launch.

What critics are saying

  • Granules settlement allows a Xywav generic under certain conditions after March 2026.
  • Jazz still carries $4.35 billion debt, with $1.0 billion 2030 notes now exchangeable.
  • Zanidatamab faces an August 25, 2026 PDUFA; rejection cripples launch expectations.

What makes Jazz Pharmaceuticals unique

  • Xywav dominates narcolepsy and idiopathic hypersomnia through low-sodium oxybate differentiation.
  • Jazz owns scarce neurology and oncology assets, including Epidiolex, Zepzelca, and Ziihera.
  • Actio acquisition on August 10, 2026 extends its rare-epilepsy precision medicine franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.

Yahoo Finance
Aug 10th, 2026
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront, adding KCNT1+ epilepsy therapy

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy, to Jazz's rare epilepsy portfolio. KCNT1+ epilepsy is a rare genetic condition affecting approximately 2,500 patients in the United States. Patients typically experience dozens to hundreds of seizures daily that resist standard medications. Around 80% of cases begin in infancy, with many children unable to reach basic developmental milestones. There are currently no FDA-approved therapies for KCNT1+ epilepsy. ABS-1230 recently showed meaningful seizure reductions in an early clinical trial. The ongoing Phase 1b/2a KYRON trial is designed as the registrational study supporting US new drug application submission.

Yahoo Finance
Aug 5th, 2026
Jazz Pharmaceuticals hits $1.2B quarterly revenue, raises full-year guidance to $4.75B on oncology surge

Jazz Pharmaceuticals reported record quarterly revenue of $1.2 billion for Q2 2026, marking a 16% year-over-year increase driven by double-digit growth across all key promoted brands. The oncology portfolio grew 32% year-over-year, supported by rapid adoption of Zepzelca in first-line maintenance and the successful launch of Modeyso. Xywav demonstrated 13% revenue growth as its low-sodium profile continues to differentiate it from high-sodium generics. The company raised its full-year revenue guidance to $4.60 billion–$4.75 billion. Jazz anticipates the 25 August PDUFA date for zanidatamab in first-line HER2-positive gastric cancers, with commercial teams prepared for immediate launch. The company is leveraging its biliary tract cancer infrastructure to support the zanidatamab rollout. Non-GAAP adjusted gross margin declined slightly due to higher sales mix of royalty-bearing products.

Yahoo Finance
Jun 23rd, 2026
Jazz Pharmaceuticals' lung cancer drug fails trial but investors spared as focus shifts to first-line treatment

Jazz Pharmaceuticals' phase 3 trial evaluating Zepzelca in second-line small-cell lung cancer failed to meet its primary endpoint of overall survival. However, the setback's impact may be limited as Zepzelca's commercial focus has already shifted. In 2025, the FDA granted full approval to Zepzelca combined with Roche's Tecentriq as a first-line maintenance treatment for extensive-stage small-cell lung cancer. That approval demonstrated a 46% reduction in disease progression risk and a 27% reduction in death risk compared with Tecentriq alone. Zepzelca sales increased 60% year over year to approximately $101 million in Q1 2026, driven by first-line maintenance adoption. The drug contributed only 7% of Jazz's total 2025 revenue of $4.3 billion, with neurological medications Xywav and Epidiolex generating significantly larger sales.